BTA-9881
BTA-9881 (MEDI-564) is a RSV inhibitor, with an EC50: 48 nM, 59 nM and 160 nM for RSV A2, RSV Long, and RSV B1. BTA-9881 has favorable pharmacokinetics property.
For research use only. We do not sell to patients.
- CAS No.: 1646857-24-0
- Formula: C21H15ClN4O2
- Molecular Weight:390.82
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEp-2 | EC50 |
0.048 μM
Compound: 33a
|
Antiviral activity against respiratory syncytial virus A2 infected in human Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against respiratory syncytial virus A2 infected in human Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25595685] |
| HEp-2 | EC50 |
0.059 μM
Compound: 33a
|
Antiviral activity against respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25595685] |
| HEp-2 | EC50 |
0.16 μM
Compound: 33a
|
Antiviral activity against respiratory syncytial virus B1 infected in human Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
Antiviral activity against respiratory syncytial virus B1 infected in human Hep2 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay
|
[PMID: 25595685] |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1646857-24-0
-
Molecular Weight 390.82
-
Formula C21H15ClN4O2
-
SMILES
O=C1N2[C@@](C3=CC=C(C=C3)Cl)(N(CC2)C(C4=CC=CN=C4)=O)C5=C1C=CN=C5
-
Synonyms
MEDI-564
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)